← All trials
NCT04401150
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Nov 30, 2021
- Completion date
- Jan 31, 2022
- First posted
- May 25, 2020
- Last posted
- May 25, 2020
- Enrollment
- 800
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of SherbrookeLead sponsor
- University of TorontoOverall official - principal investigator
- Lotte & John Hecht Memorial FoundationCollaborator
- University of SherbrookeOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.